Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Vlad always manages to conjure up an RNS when he is looking for investment, look at all those conferences he has been to , and we have seen zero impact from those.
Shareholders havent even been shown what the new lab looks and as for the website !!!!!!
Good luck ... hope nothing happens if you get too greedy and your money gets stuck for 6 months like for those pour investors in 4D !!!
I'll probably cave in and buy around current price MrIndia...giving GOG one more week for a counter offer then going to have to make a choice
I love your games Barber ... You trying to spread fear so that people sell. Nice one. Most people are loaded and will be loading more for the AGM and investor update next week. Why would anyone sell so close to possible news unless they desperate to help you get a lower price?
For the sake of 5 or 10% why not buy now like you keep threatening to do???
When it hits 1.15p will be buying more....just a waiting game...
I think it was an RCS ... not sure what the difference is but I actually do believe they put out a formal comms on this since they will be announcing something that could affect the share price. Surprised not more people buying in yet ....
It is interesting that a webinar is the subject of an RNS when arguably other significant events are not.
Does this suggest more news will emerge in the intervening period....
Let's hope all those with money:find Hemo and invest! Just saw a pig fly past
Mr India I agree. I would also note that the so called safe haven of crypto has taken a turn and far more investors are likely to return to small caps. Finally the heads up from the G7 looks as though Ukraine is going to push for a blitz on Russian troops in August, with substantial armoury being delivered to allow them to end the war later this year, and despite what Pumpkin says that May allow a substantial part of the £8bn that investors have withdrawn to come back to the market, just in time for Hemogenyx t become clinical.
I'm sure there are a lot of people buying at this price:ready to dump them for a 20% profit;should be a AIM share
Worth remembering as MrIndia points out, these are events that vlad has CHOSEN to do, he wants to involve shareholders and provide more information. He is doing it because he loves the science and is excited, some will join looking only for a snippet of information on which they can trade. A line to justify them dumping or buying. Its sad its like that,but I hope that Vlad bears that in mind and does not say too much in terms of exact timelines, I want him to neither give the impression of news imminent or long in the distance.
Big news should catch us all by surprise and give no advantage to traders who wish to trade/buy at the last minute and dump on update. That said, its fair to assume there will be updates soon, his interview did allude that the Master cell line work with selenix was almost finished and it was several months ago the un-named partner started working with Hemo to validate CBR in the level 3 facility.
HFH ... A few reasons (purely personal) that If i had money, i would invest at this low price :-
- HEMO has money to get through to clinical trials in Q1. This is critical for our main product and as we saw from the failure of 4D on friday, is critical to build confidence in pharma. Nothing is guaranteed though of course
- At this low price, the downside is minimal. Again just my feeling since everything negative is factored in. Any positive news on any partnerships, money or licencing will drive this skywards and quick. We know how fast hemo can move
- The current interview hints at many many things so reason to be hopeful something is imminent
- I am fairly sure money is being held on the sidelines by investors who are waiting for a good update. That could happen on the 6th and that could be the stimulus this stock needs
- We know money is coming back into Pharma and this again is a very undervalued stock compared to anything mid or big pharma.
- Lastly and yes I also think there will be regular updates on CART like clean rooms and other items over the coming 6 months ... again, we don't need much to bring back positivity into this stock which is rock bottom
I have done much analysis and asked a few people and will definately be hanging on and even buying more soon if anything positive arrives on the scene ....
I think you are right that a CDX update will be issued soon, maybe sooner than CBR. You are also correct in saying that we are unlikely to hear anything on CAR until the end of the year, unless they announce something pertaining to the clean rooms being fully functional. All in my opinion.
You are never happy with my statements and thats fine ... i am not here to please you or your followers. I just stated that I think and feel an RNS is coming. Listen to the interview at the end where the interviewer asks about things that could rerate the share price ... he says he cannot say. The call was planned for AGM day ... now a week later. yes I am making an assumption that something is brewing since we don't expect a major update on CART now for a little time but CBR and CDX are in full throttle behind the scene and why do a call and say nothing to displease investors ... I hope for an RNS before the 6th and he can then address it in a positive manner on the day !!!
Mr india how have you come to that concept ? So now we will expect a possitive rns by the 6th then? As say it what its means ?? Since when have you had inside info ???? What a stupid statement
HFH ... I am off the same belief. He initially said on the interview, the call would be that day. It is pushed out to 6th ... That can only mean they are writing or preparing an RNS announcement. I also think a partnership on CBR as that he hinted on the call but couldn't say YET !!!
The eternal pessimist becomes the long term optimist !!
What is critical is getting HEMO CAR-T into clinical trials and that’s exactly what they are doing. However, that doesn’t mean an announcement on a partnership on CBR would not be welcome. I’ve registered so I’ll see you there. Could be an interesting couple of weeks.
The AGM is this week but this call is on the 6th ... I hope the delay is so he can announce something interesting for the share price to rerate. With the collapse of 4d, partnerships and getting investment into HEMO is critical and this low share price will not allow that. Let's hope his CFO can advise him of what is needed ....
Oh no:another Vlad interview:we all know what happens to the SP after
What we need imo is a JV with financial diligence.
The work with Merck at 4D doesn’t automatically turn them into a white knight as it wasn’t that type of deal.
You can also add SNG and IMM to recent SP woes.
The rewards of autonomy were/are potentially huge but the market seems to prefer a more shared risk approach. Better to have improved financial security and give up some of the pie early on which is part of the higher risk end.
SNG from memory raised around £87m (170p ish) for a phase 3 trial which came quickly on the back of a 14m raise at 35p ish.
For sure the progress made at phase 2 meant that the sp was much higher at phase 3.
Hence I took 2.5 x my money out between the two placings allowing the rest to ride only to virtually disintegrate when p3 didn’t show statistical differentiation. I sold what I had and then bought the dip and sold the lot again salvaging a little more.
What’s the point of this missive.
Well I think, not teaching anyone to suck eggs, but those newer to biotech, mining or O&G investing need to really think about how they wish to play their hands.
Don’t go falling for the Warren Buffet quotes about time in the market etc he probably wouldn’t touch anything in the small cap space so his ‘moat rules’ don’t apply!
4D was one of my best ever investments and it’s actually a sad day for Duncan, the team, pts and investors alike. I hope they can save the company but the lessons there are worth learning for all.
Nothing worse imo than being blinkered by one share when there is free experience available both good and not so good.
Some of the holdings here are super high albeit it’s all relative. Some folk have had opportunities to get a free carry in the past and turned it down.
All I am saying is give any opportunity in this space to derisk profits serious thought.
How many now at ARB would be happy with my last sell at 150p or AVCT at 200p. Whilst it wasn’t the top far from it.
Even just keeping a smaller position gives one the option to always buy back in! And it also helps offset some inevitable losses!
I am pretty sure we will be faced with a decision to be made here soon. Let’s hope so!
Usual caveats
Trek
Unfortunately 4D pharma shows the risk involved aswell as the cash burn during trails. Fortunately Hemo have exited loan agreements and have £6m cash in the bank but as Vlad has mentioned, clinical trails will burn through cash quickly.
The company needs to make either rising funds or rising the SP to sustain a placing priority!
I don't think the news from 4D will make investors rush into low mcap biotech quickly.